Sonoma Pharmaceuticals (SNOA) Retained Earnings (2011 - 2026)

Sonoma Pharmaceuticals' Retained Earnings history runs 16 years deep, the most recent figure standing at -$201.0 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 4492.8% year-over-year to -$201.0 million in Q1 2026; TTM through Mar 2026 was -$201.0 million, a 4492.8% decrease from a year earlier, with the FY2026 full-year figure at -$201.0 million, down 4492.8% from the prior year.
• Retained Earnings held at -$201.0 million in Q1 2026 per SNOA's latest filing, from -$200.4 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$2.8 million in Q4 2023 and bottomed at -$201.0 million in Q1 2026.
• The 5-year median for Retained Earnings is -$4.6 million (2024), against an average of -$94.3 million.
• Across the five-year window, Retained Earnings surged 98.32% in 2023 and slumped 5586.04% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$4.2 million in 2022, then soared by 32.4% to -$2.8 million in 2023, then sank by 61.32% to -$4.6 million in 2024, then tumbled by 4300.53% to -$200.4 million in 2025, then dropped by 0.29% to -$201.0 million in 2026.
• Per Business Quant, the three latest SNOA Retained Earnings figures stand at -$201.0 million (Q1 2026), -$200.4 million (Q4 2025), and -$199.6 million (Q3 2025).